Sequential versus concurrent chemo-radiotherapy in inoperable stage III non-small cell lung cancer.

Full Abstract

AIM:
To define the best sequence of radiotherapy and chemotherapy for inoperable stage III non-small cell lung (NSCL) tumours.

MATERIALS AND METHODS:
A systematic review was performed on the clinical results of radiotherapy, combined or not with chemotherapy, for inoperable NSCL cancer stage III. The mean median survival time (MST) and mean overall survival (OS) percentages were derived for radiotherapy only, for sequential and for concurrent chemo-radiotherapy.

RESULTS:
The mean median survival duration +/- standard deviation for radiotherapy only was 10.4 +/- 1.8 months. For sequential chemo- and radiotherapy it was increased to 13.0 +/- 1.2 months. When radiotherapy in the sequential regimen was accompanied by chemotherapy, the mean median duration was 15.8 +/- 2.6 months. For concurrent radio-chemotherapy it was further increased to 16.4 +/- 2.7 months. The mean 2- and 3-year overall survivals for radiotherapy alone, sequential and concurrent radio-chemotherapy were 17.1 +/- 4.6 and 10, 23.8 +/- 6.3 and 18.5 +/- 7.0, and 32.5 +/- 8.7 and 25.7 +/- 6.3%, respectively.

CONCLUSION:
Concurrent chemo-radiotherapy demonstrated increased efficacy over sequential chemotherapy and radiotherapy and should be the treatment of choice. Further improvements may be obtained by optimising the conditions for concurrent chemo-radiotherapy.

Learn Faster Today Improve your study skills

Author information

Author/s: El-Sharouni, S Y (SY); Kal, H B (HB); Battermann, J J (JJ); Schramel, F M N H (FM);

Affiliation: Department of Radiotherapy, University Medical Centre, Utrecht, The Netherlands. S.Y.ElSharouni(-atsign-)azu.nl

Journal and publication information

Publication Type: Journal Article; Review

Journal: Anticancer research (Anticancer Res), published in Greece. (Language: eng)

Reference: -2006 Jan-Feb; vol 26 (issue 1B) : pp 495-505

Dates: Created 2006/06/02; Completed 2006/06/12; Revised 2007/11/15;

PMID: 16739310, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Carcinoma, Non-Small-Cell Lung - drug therapy; pathology; radiotherapy
Combined Modality Therapy
Dose Fractionation
Drug Administration Schedule
Humans

Humans
Lung Neoplasms - drug therapy; pathology; radiotherapy
Meta-Analysis as Topic
Neoplasm Staging
Survival Rate

These are the highest related articles currently in the database:

See 100+ related articles.